

Global Cancer Vaccine Market & Clinical Trial Insight 2025

URL: <https://marketpublishers.com/r/G64AE2785D3EN.html>

Date: September 1, 2018

Pages: 700

Price: US\$ 3,000.00

ID: G64AE2785D3EN

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Cancer Vaccine Market & Clinical Trial Insight 2025' Report Highlight:

- Global Cancer Vaccine market Opportunity: US\$ 15 Billion Opportunity
- Personalized Cancer Vaccine: The Next growth Frontier
- Global Cancer Vaccine Clinical insight by Indication & Phase of Development
- Global Cancer Vaccine Pipeline: 369 Cancer Vaccines
- Marketed Cancer Vaccines: 17 Cancer Vaccines
- Maximum Vaccines in Pipeline for Brain & Breast Cancer: 43 Cancer Vaccines
- Regulatory Landscape

Global cancer vaccine market opportunity is expected to surpass US\$ 15 Billion by 2025 as per finding in new research report “Global Cancer Vaccine Market & Clinical Trial Insight 2025” published by PNS Pharma. In recent years, cancer vaccine segment as emerged as next growth frontier for the various stake holders involved in the research, development and commercialization of cancer therapeutics. The market for cancer therapeutics is growing at significant rates and it has already occupied a major share in the overall pharmaceutical market.

Vaccines have had a good reputation when it comes to their safety and therapeutic outcome. The concept of vaccination has today paved a new path for treatment of complex disease like cancer, the cure for which is still highly limited to conventional therapeutics. However, with the emergence of immunotherapy, the cancer therapy segment has also advanced to a whole new level.

The application of the concept of vaccination to complex disease like cancer has grabbed immense attention in both academia and industries. Multiple clinical studies have shown that an ideal vaccine for cancer is in fact possible with the help of modern immunotherapy and advanced therapy. However, the study has further being extended with rigorous effort being put in the development of personalized cancer vaccine which are anticipated to have even better therapeutic outcome than cancer vaccines .

Owing to the advancement in science and technology along with the emergence of advanced computing, few cancer vaccines like cervarix for cervical cancer and provenge for prostate cancer have already entered the market. Both the vaccines are therapeutic vaccines which have shown excellent outcome in the clinical trials. The emergence of genome sequencing and ability to identify and target neo – antigens has led to the possibility of these vaccines being developed for many types of cancer in a more personalized form in the future.

The cancer vaccine pipeline is expected to increase at tremendous rates in coming years. As large numbers of cancer vaccines are entering in various phases of clinical trials, due to which cancer market will soon observe a boost. However, the novelty of cancer vaccines makes it difficult for the standardization of clinical trials, because the criteria's required to quantify its effectiveness are not completely discovered, this cause loss of valuable time. Moreover, the present day methods are standardized for conventional cancer

therapeutic methods like chemotherapy, radiotherapy and surgery, which are not applicable for cancer vaccines due to their different mode of actions. In near future, researchers will find the solution for this problem and it will decrease the winding time.

“Global Cancer Vaccine Market & Clinical Trial Insight 2025” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer vaccines. As per report findings, there are 17 cancer vaccines commercially available in the market and more than 350 in the clinical pipeline. Most of the cancer vaccines in clinical pipeline are in Preclinical & Phase - II trials followed by Phase - I/II trials. More than 5 new cancer vaccines are further expected to enter the market in next 10 years.

Table of Content

1. INTRODUCTION TO CANCER VACCINES

2. MECHANISM OF CANCER VACCINES

- 2.1 Idiotype Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. GLOBAL CANCER VACCINES MARKET OVERVIEW

- 3.1 Current Scenario
- 3.2 Future Outlook

4. PERSONALIZED CANCER VACCINE: THE NEXT GROWTH FRONTIER

- 4.1 The Possibility of a Personalized Cancer Vaccine
- 4.2 An Insight into its Current Clinical Status

5. PERSONALIZED CANCER VACCINE: CURRENT MARKET SCENARIO & ADVANCEMENTS

- 5.1 Breakthrough in Research & Development
- 5.2 Increasing Investments
- 5.3 Integration of mRNA Technology
- 5.4 Collaborations & Ventures
- 5.5 Advancement in Technology

6. FDA GUIDELINE FOR THE DEVELOPMENT & MARKETING OF CANCER VACCINES

- 6.1 Considerations for Both Early and Late Phase Clinical Trials
 - 6.1.1 Patient Population
 - 6.1.2 Monitoring The Immune Response
 - 6.1.3 Biomarkers As Evidence Of Efficacy
 - 6.1.4 Adjuvants Used To Stimulate Immune Response
 - 6.1.5 Multi-Antigen Vaccines
 - 6.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
 - 6.1.7 Concomitant And Subsequent Therapies

- 6.2 Considerations for Early Phase Clinical Trials
 - 6.2.1 Starting Dose And Dosing Schedule
 - 6.2.2 Booster And Maintenance Therapy
 - 6.2.3 Dose Escalation
 - 6.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
- 6.3 Considerations For Late Phase Clinical Trials
 - 6.3.1 Safety Profile From Early Phase Clinical Trials
 - 6.3.2 Endpoints
 - 6.3.3 Statistical Issues
 - 6.3.4 Control Issues
 - 6.3.5 Delayed Vaccine Effect
 - 6.3.6 Autologous Vaccine Trials
 - 6.3.7 Accelerated Approval Regulations

7. GLOBAL CANCER VACCINES CLINICAL PIPELINE OVERVIEW

- 7.1 By Indication
- 7.2 By Mechanism of Action
- 7.3 By Drug Class
- 7.4 By Patient Segment
- 7.5 By Formulation
- 7.6 By Company

8. GLOBAL - BLADDER CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 8.1 Phase-I/II

9. MARKETED BLADDER CANCER VACCINE CLINICAL INSIGHT

- 9.1 BCG Bladder Cancer Vaccine - sanofi pasteur
- 9.2 Bladder Cancer Vaccine - Organon Teknika
- 9.3 Bladder Cancer Vaccine - ID Biomedical

10. GLOBAL - BLOOD CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 10.1 Research
- 10.2 Preclinical
- 10.3 Phase-I
- 10.4 Phase-I/II
- 10.5 Phase-II

11. GLOBAL - BONE CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 11.1 Phase-II
- 11.2 Phase-III

12. GLOBAL - BRAIN CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 12.1 Unknown
- 12.2 Research
- 12.3 Preclinical
- 12.4 Phase-I
- 12.5 Phase-I/II
- 12.6 Phase-II
- 12.7 Phase-III

13. GLOBAL - BREAST CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 13.1 Research
- 13.2 Preclinical
- 13.3 Phase-I
- 13.4 Phase-I/II
- 13.5 Phase-II
- 13.6 Phase-II/III
- 13.7 Phase-III

14. GLOBAL - CERVICAL CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 14.1 Preclinical
- 14.2 Clinical
- 14.3 Phase-I
- 14.4 Phase-II
- 14.5 Phase-III

15. MARKETED CERVICAL CANCER VACCINE CLINICAL INSIGHT

- 15.1 Cervarix

16. GLOBAL - COLORECTAL CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 16.1 Research
- 16.2 Preclinical
- 16.3 Phase-I
- 16.4 Phase-I/II
- 16.5 Phase-II
- 16.6 Phase-II/III
- 16.7 Phase-III

17. GLOBAL - KIDNEY CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 17.1 Preclinical
- 17.2 Phase-I
- 17.3 Phase-II
- 17.4 Phase-III

18. MARKETED KIDNEY CANCER VACCINE CLINICAL INSIGHT

- 18.1 Vitespen (Oncophage)
- 18.2 Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
- 18.3 Renal Cell Carcinoma Vaccine (Reniale)

19. GLOBAL - LIVER CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 19.1 Phase-I/II
- 19.2 Phase-II
- 19.3 Phase-III

20. GLOBAL - LUNG CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 20.1 Preclinical

21. GLOBAL - MESOTHELIOMA VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 21.1 Phase-I
- 21.2 Phase-II/III

22. GLOBAL - HEAD AND NECK CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 22.1 Preclinical
- 22.2 Phase-I
- 22.3 Phase-I/II
- 22.4 Phase-II

23. GLOBAL - NON SMALL CELL LUNG CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 23.1 Research
- 23.2 Clinical
- 23.3 Phase-I
- 23.4 Phase-I/II
- 23.5 Phase-II
- 23.6 Phase-II/III
- 23.7 Phase-III
- 23.8 Preregistration

24. MARKETED NON SMALL CELL LUNG CANCER VACCINE CLINICAL INSIGHT

- 24.1 Cadi 05 (Immuvac & Mycidac-C)
- 24.2 Racotumomab (Vaxira)
- 24.3 Epidermal Growth Factor Cancer Vaccine – Bioven

25. GLOBAL - OVARIAN CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 25.1 Preclinical
- 25.2 Phase-I
- 25.3 Phase-I/II
- 25.4 Phase-II
- 25.5 Phase-III

26. GLOBAL - PROSTATE CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 26.1 Research
- 26.2 Preclinical
- 26.3 Phase-I
- 26.4 Phase-I/II
- 26.5 Phase-II
- 26.6 Phase-III

27. MARKETED PROSTATE CANCER VACCINE CLINICAL INSIGHT

- 27.1 Sipuleucel-T (Provenge)

28. GLOBAL - PANCREATIC CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 28.1 Preclinical

- 28.2 Phase-I
- 28.3 Phase-I/II
- 28.4 Phase-II
- 28.5 Phase-III

29. MARKETED PANCREATIC CANCER VACCINE CLINICAL INSIGHT

- 29.1 Tertomotide (LucaVax)

30. GLOBAL - SKIN CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 30.1 Preclinical
- 30.2 Phase-I
- 30.3 Phase-I/II
- 30.4 Phase-II
- 30.5 Phase-III
- 30.6 Preregistration

31. MARKETED SKIN CANCER VACCINE CLINICAL INSIGHT

- 31.1 Melanoma Vaccine (MVax)
- 31.2 Melanoma Vaccine (Melacine)

32. GLOBAL - MULTIPLE CANCER VACCINE CLINICAL PIPELINE BY PHASE & COMPANY

- 32.1 Research
- 32.2 Preclinical
- 32.3 Clinical
- 32.4 Phase-I
- 32.5 Phase-I/II
- 32.6 Phase-II
- 32.7 Phase-III
- 32.8 Registered

33. MARKETED MULTIPLE CANCER VACCINE CLINICAL INSIGHT

- 33.1 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
- 33.2 Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil & Silgard)
- 33.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

34. COMPETITIVE LANDSCAPE

- 34.1 Advaxis
- 34.2 AVAX Technologies
- 34.3 Dendreon Corporation
- 34.4 Galena Biopharma
- 34.5 GlaxoSmithKline
- 34.6 ImmunoCellular Therapeutics
- 34.7 ImmunoGen
- 34.8 Inovio Pharmaceuticals
- 34.9 KAEL-GemVax
- 34.10 Liponova
- 34.11 MedImmune
- 34.12 Merck
- 34.13 NeoStem Oncology

- 34.14 NewLink Genetics
- 34.15 Northwest Biotherapeutics
- 34.16 Novartis
- 34.17 Peregrine Pharmaceuticals
- 34.18 Recombio
- 34.19 Roche
- 34.20 Sanofi
- 34.21 Seattle Genetics
- 34.22 Valeant Pharmaceuticals

LIST OF FIGURES

- Figure 1-1: Categorization & Function of Cancer Vaccines
- Figure 2-1: Classification of Different Types of Cancer vaccines
- Figure 3-1: Global - Cancer Vaccines Market Opportunity (US\$ Billion), 2018-2025
- Figure 3-2: Examples of Commercially Available Cancer Vaccines
- Figure 4-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
- Figure 4-2: Advantages of Targeting Neo – Antigens in Cancer Vaccine Production
- Figure 5-1: Investments Generated by Key Market Players in the Personalized Cancer Segment (US\$ Million), 2018
- Figure 7-1: Global - Bladder Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-2: Global - Bladder Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-3: Global - Blood Cancer Vaccine Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-4: Global - Blood Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-5: Global - Bone Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-6: Global - Bone Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-7: Global - Brain Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-8: Global - Brain Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-9: Global - Breast Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-10: Global - Breast Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-11: Global - Cervical Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-12: Global - Cervical Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-13: Global – Colorectal Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-14: Global – Colorectal Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-15: Global – Kidney Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-16: Global – Kidney Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-17: Global – Liver Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-18: Global – Liver Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-19: Global – Mesothelioma Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-20: Global – Mesothelioma Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-21: Global – Head and Neck Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-22: Global – Head and Neck Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-23: Global – Non Small Lung Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-24: Global – Non Small Lung Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-25: Global – Ovarian Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-26: Global – Ovarian Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-27: Global – Prostate Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-28: Global – Prostate Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-29: Global – Pancreatic Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-30: Global – Pancreatic Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-31: Global – Skin Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-32: Global – Skin Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025
- Figure 7-33: Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025
- Figure 7-34: Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-35: Total Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-36: Total Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-37: Global –Cancer Vaccines Clinical Pipeline by Mechanism of Action (%), 2018 Till 2025

Figure 7-38: Global –Cancer Vaccines Clinical Pipeline by Mechanism of Action (Number), 2018 Till 2025

Figure 7-39: Global – Cancer Vaccines Clinical Pipeline by Drug Class (%), 2018 Till 2025

Figure 7-40: Global – Cancer Vaccines Clinical Pipeline by Drug Class (Number), 2018 Till 2025

Figure 7-41: Global – Cancer Vaccines Clinical Pipeline by Patient Segment (%), 2018 Till 2025

Figure 7-42: Global – Cancer Vaccines Clinical Pipeline by Patient Segment (Number), 2018 Till 2025

Figure 7-43: Global – Cancer Vaccines Clinical Pipeline by Formulation (%), 2018 Till 2025

Figure 7-44: Global – Cancer Vaccines Clinical Pipeline by Formulation (Number), 2018 Till 2025

Figure 7-45: Global – Cancer Vaccines Clinical Pipeline by Company (%), 2018 Till 2025

Figure 7-46: Global – Cancer Vaccines Clinical Pipeline by Company (%), 2018 Till 2025

I would like to order:

Product name: Global Cancer Vaccine Market & Clinical Trial Insight 2025
Product link: <https://marketpublishers.com/r/G64AE2785D3EN.html>
Product ID: G64AE2785D3EN
Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/G64AE2785D3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**